DMEMEDS shared post via NYT: Afrezza, a New Inhaled Insulin, Is Approved by the F.D.A.

The approval is a huge milestone for MannKind Corporation, but concerns linger about the drug's potential effect on patients' lungs. [Category: Pfizer Inc|PFE|NYSE, Drugs (Pharmaceuticals), Food and Drug Administration, MannKind Corporation|MNKD|NASDAQ, Insulin, Medtronic Inc|MDT|NYSE, Diabetes] http://rss.nytimes.com/c/34625/f/640346/s/3bf5f5b4/sc/14/l/0L0Snytimes0N0C20A140C0A60C280Cbusiness0Cafrezza0Ea0Enew0Einhaled0Einsulin0Eis0Eapproved0Eby0Efda0Bhtml0Dpartner0Frss0Gemc0Frss/story01.htm

Read More